Cetuximab biosimilar (Shanghai Zhangjiang Biotechnology)
- Generic Name
- Cetuximab biosimilar (Shanghai Zhangjiang Biotechnology)
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 520
- Registration Number
- NCT03206151
- Locations
- 🇨🇳
Cancer hospital Chinese academy of medical sciences, Beijing, Beijing, China
🇨🇳Tianjing medical university cancer institute and hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath